421 related articles for article (PubMed ID: 7622824)
1. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
[TBL] [Abstract][Full Text] [Related]
2. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Figgitt DP; McClellan KJ
Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
[TBL] [Abstract][Full Text] [Related]
3. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
Den Boer JA; Westenberg HG
Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
5. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.
Zohar J; Westenberg HG
Acta Psychiatr Scand Suppl; 2000; 403():39-49. PubMed ID: 11019934
[TBL] [Abstract][Full Text] [Related]
6. Serotonin-influencing drugs in the treatment of panic disorder.
Westenberg HG; den Boer JA
Psychopathology; 1989; 22 Suppl 1():68-77. PubMed ID: 2498967
[TBL] [Abstract][Full Text] [Related]
7. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
Dell'Osso B; Allen A; Hollander E
Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression].
Semba J
Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):79-84. PubMed ID: 10976459
[TBL] [Abstract][Full Text] [Related]
10. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo.
Peter H; Tabrizian S; Hand I
Int J Psychiatry Med; 2000; 30(1):27-39. PubMed ID: 10900559
[TBL] [Abstract][Full Text] [Related]
11. [Selective serotonin reuptake inhibitor(SSRI)].
Motohashi N
Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
13. [Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors].
Yamauchi M; Hiraoka S; Imanishi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):193-8. PubMed ID: 17240844
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
Gunasekara NS; Noble S; Benfield P
Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan].
Hachisu M; Ichimaru Y
Nihon Yakurigaku Zasshi; 2000 May; 115(5):271-9. PubMed ID: 10872178
[TBL] [Abstract][Full Text] [Related]
16. Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients.
Peter H; Hand I; Hohagen F; Koenig A; Mindermann O; Oeder F; Wittich M
Can J Psychiatry; 2002 Aug; 47(6):557-61. PubMed ID: 12211884
[TBL] [Abstract][Full Text] [Related]
17. Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
den Boer JA
J Clin Psychiatry; 1997; 58 Suppl 8():17-9. PubMed ID: 9236731
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on paroxetine in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin-reuptake inhibitors: an update.
Masand PS; Gupta S
Harv Rev Psychiatry; 1999; 7(2):69-84. PubMed ID: 10471245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
